Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net Loss per Common Share

Net Loss per Common Share

9 Months Ended

Sep. 30, 2020

13. Net Loss per Common Share

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of Common Stock outstanding during the period, without consideration for Common Stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of Common Stock and Common Stock equivalents outstanding for the period.

The following shares of potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding, as the effect of including such securities would be anti-dilutive for the nine months ended September 30, 2020:


	Nine Months Ended September 30,
	2020	2019
Warrants to purchase Common Stock	3,026,693	2,745,364
Options to purchase Common Stock	1,187,600	1,169,293
Unvested Restricted Stock	14,305,949	12,622,881
Unvested Restricted Stock Units	434,215	791,610
Total	18,954,457	17,329,148